Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06293053
Other study ID # PKM17836
Secondary ID U1111-1287-7255
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 15, 2024
Est. completion date November 3, 2027

Study information

Verified date May 2024
Source Sanofi
Contact Trial Transparency email recommended (Toll free for US & Canada)
Phone 800-633-1610
Email Contact-US@sanofi.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: - Screening period: 2 to 4 weeks. - Treatment period: 24 weeks. - Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). The total number of planned study visits for each participant will be 6.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date November 3, 2027
Est. primary completion date October 28, 2027
Accepts healthy volunteers No
Gender All
Age group 6 Months to 17 Years
Eligibility Inclusion Criteria: - Participants must be =6 months to <18 years of age, at the time of signing the informed consent. - A clinical diagnosis of prurigo nodularis (PN) at least 3 months prior to screening, an Investigator's global assessment for prurigo nodularis stage (IGA PN-S) score of =2 with presence of =6 pruriginous lesions at Baseline. The lesions should be present on =2 different body surface areas at Baseline. - On the worst itch numerical rating scale (WI-NRS) (for participants aged =6 years to <18 years old at the screening visit) or worst-scratch/itch NRS (for participants aged =6 months to <6 years at the screening visit) ranging from 0 to 10, participants must have an average worst itch score of =7 in the 7 days prior to Day 1. NOTE: Baseline pruritus NRS average score for maximum itch intensity will be determined based on the average of daily NRS scores for maximum intensity (the daily score ranges from 0 to 10) during the 7 days immediately preceding the Day 1/Baseline visit. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. - Participants/Caregivers must be willing and able to complete a daily symptom e-Diary for the duration of the study. - Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: - Presence of active moderate to severe lesions of atopic dermatitis (AD), and/or other skin conditions that may interfere with the PN diagnosis including but not limited to the following: scabies, psoriasis, lymphomatoid papulosis, habitual picking, dermatitis herpetiformis, sporotrichosis, and bullous disease. - Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period. NOTE: Participants may be rescreened after infection resolves. - Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator. - Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study. - Planned or anticipated major surgical procedure during the participant's participation in this clinical trial. - Participants who has taken biologic therapy/systemic immunosuppressant/ immunomodulator within 4 weeks before the screening visit or 5 half-lives, whichever is longer. - Current participation to any clinical trial of an investigational drug or device or participation within 3 months before the screening visit or 5 half-lives of the investigational compound, whichever is longer. - Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dupilumab
Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Locations

Country Name City State
United States Pediatric Center Of Excellence Site Number : 8400005 Coral Gables Florida
United States Mission Dermatology Center Site Number : 8400011 Rancho Santa Margarita California
United States Vital Prospects Clinical Research Institute, P.C. Site Number : 8400002 Tulsa Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
Sanofi Regeneron Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of dupilumab in serum Concentration of dupilumab in serum over time Day 1 to Week 40
Secondary Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) Date of signed ICF (2-4 weeks before Day 1) to Week 40
Secondary Incidence of anti-drug antibodies (ADA) to dupilumab over time Day 1 to Week 40
See also
  Status Clinical Trial Phase
Completed NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Phase 2
Completed NCT00869089 - Safety and Efficacy of CC-10004 for Prurigo Nodularis Phase 2
Completed NCT04501666 - An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis Phase 3
Completed NCT03181503 - Safety and Efficacy of Nemolizumab in PN Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT04944862 - A Study of CDX-0159 in Patients With Prurigo Nodularis Phase 1
Completed NCT05061693 - A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis Phase 2
Completed NCT03546816 - Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Phase 3
Not yet recruiting NCT06201715 - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis N/A
Completed NCT02174419 - Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Phase 2/Phase 3
Terminated NCT03540160 - Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) Phase 3
Recruiting NCT06427122 - Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life N/A
Completed NCT03816891 - Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis Phase 2
Recruiting NCT05764161 - A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Phase 3
Completed NCT02196324 - A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Phase 2
Not yet recruiting NCT06424470 - Study on the Treatment of Prurigo Nodularis With Stapokibart Injection Phase 3
Recruiting NCT03576287 - Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Phase 1/Phase 2
Completed NCT05052983 - A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis Phase 3
Active, not recruiting NCT04204616 - A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Phase 3
Recruiting NCT06213831 - A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream Phase 1